Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more ‘public’

One of the obstacles of personalized medicine is that it is, well, personalized. With cancer therapies especially, personalized treatments take money, time, resources and access — all of which are finite.

But some scientists instead want to take a more “public” approach to what has traditionally been a therapy tailored...

Click to view original post